Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Ergomed plc
  6. News
  7. Summary
    ERGO   GB00BN7ZCY67

ERGOMED PLC

(ERGO)
  Report
Delayed Quote. Delayed London Stock Exchange - 07/29 09:39:49 am
1158.7499 GBX   -3.03%
07/27FTSE Closes Down on China's Hang Seng Index Sliding to Nine-Month Lows
DJ
07/27ERGOMED : H1 2021 Trading Update
PU
07/27FTSE Falls as Miners, Banks and Reckitt Drop
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Edison Investment Research Limited: Ergomed (ERGO): What's next after stellar 2020 performance?

06/02/2021 | 03:01am EDT
Edison Investment Research Limited 
Edison Investment Research Limited: Ergomed (ERGO): What's next after stellar 2020 performance? 
02-Jun-2021 / 08:00 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
 
London, UK, 2 June 2021 
 
Ergomed (ERGO): What's next after stellar 2020 performance? 
Although most of 2020 was challenging for the contract research outsourcing (CRO) sector, for Ergomed it was a 
transformative growth period due to well-balanced pharmacovigilance (PV) and CRO offerings. Ergomed managed to 
withstand global woes caused by the COVID-19 pandemic and delivered another solid year of growth, organically and 
through acquisitions. We believe the company will continue to benefit from a clear strategic focus (oncology, rare 
diseases and pharmacovigilance), order book growth and margin control and strong secular CRO sector growth. Our 
valuation of GBP683m or 1,400p/share is virtually unchanged. 
 
We maintain our estimates and our valuation is virtually unchanged at GBP683m or 1,400p/share derived from our DCF model 
implying an EV/EBITDA multiple of 30.5x based on our FY21 forecasts. We note that Ergomed trades at a premium EV/EBITDA 
(FY21e) of 26.9x compared to the peer average of 20.0x (in line with Medpace). In this report, we analyse the 
sensitivity of our valuation to a set of DCF assumptions (long-term sales growth and profit margins). We find that a 
bull case would correspond to a valuation of 1,950p/share, while a bear case 995p/share. The AGM trading update in June 
2021 and full H121 trading update in July 2021 are the next catalysts. 
Click here to view the full report or here to sign up to receive research as it is published. 
 
All reports published by Edison are available to download free of charge from its website 
www.edisongroup.com 
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the 
widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, 
family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the 
darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings. 
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. 
Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in 
Athens, Johannesburg and Sydney. 
Edison is authorised and regulated by the Financial Conduct Authority. 
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not 
solicitations to buy or sell any securities. 
For more information, please contact Edison: 
Dr Jonas Peciulis +44 (0)20 3077 5728 healthcare@edisongroup.com 
Dr Sean Conroy  +44 (0)20 3077 5700 healthcare@edisongroup.com 
Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn        https://www.linkedin.com/company/edison-group-/ 
Twitter           www.twitter.com/Edison_Inv_Res 
YouTube       www.youtube.com/edisonitv 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 

1203167 02-Jun-2021

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1203167&application_name=news 
 

(END) Dow Jones Newswires

June 02, 2021 03:00 ET (07:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
0X (ZRX/USD) 6.51% 0.74334 Real-time Quote.101.21%
DJ INDUSTRIAL 0.55% 35144.76 Delayed Quote.14.55%
ERGOMED PLC -3.03% 1158.7499 Delayed Quote.9.83%
MEDPACE HOLDINGS, INC. 0.76% 175.745 Delayed Quote.25.50%
All news about ERGOMED PLC
07/27FTSE Closes Down on China's Hang Seng Index Sliding to Nine-Month Lows
DJ
07/27ERGOMED : H1 2021 Trading Update
PU
07/27FTSE Falls as Miners, Banks and Reckitt Drop
DJ
07/27FTSE Down, Pound Likely to Rise as BOE Moves Closer Towards Tightening
DJ
06/17ERGOMED : Syncona CFO Retires, Successor Appointed
MT
06/14ERGOMED (ERGO) : FY21e EBITDA 'materially ahead' of consensus
DJ
06/11ERGOMED : Annual General Meeting Statement
AQ
06/10ERGOMED : Expects 2021 Adjusted EBITDA to Beat Consensus
MT
06/10ERGOMED : Annual General Meeting Statement
PU
06/02EDISON INVESTMENT RESEARCH LIMITED : Ergomed (ERGO): What's next after stellar 2..
DJ
More news
Financials
Sales 2021 120 M 167 M 167 M
Net income 2021 12,8 M 17,9 M 17,9 M
Net cash 2021 29,3 M 40,9 M 40,9 M
P/E ratio 2021 45,4x
Yield 2021 -
Capitalization 583 M 810 M 815 M
EV / Sales 2021 4,63x
EV / Sales 2022 4,00x
Nbr of Employees 1 150
Free-Float 73,1%
Chart ERGOMED PLC
Duration : Period :
Ergomed plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERGOMED PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1 195,00 GBX
Average target price 1 490,00 GBX
Spread / Average Target 24,7%
EPS Revisions
Managers and Directors
Richard Timothy Barfield Chief Financial Officer & Executive Director
Miroslav Reljanovic Executive Chairman
Gordana Tonkovic Head-Clinical Development
Sladana Sturlic Head-Clinical Operations
Lewis Cameron Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
ERGOMED PLC9.83%810
GILEAD SCIENCES, INC.20.25%87 868
BIONTECH SE284.51%75 705
WUXI APPTEC CO., LTD.36.10%68 994
REGENERON PHARMACEUTICALS21.38%60 726
VERTEX PHARMACEUTICALS-14.43%52 353